USPTO serial 79404957
CONFOGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 5, 2025
- Examiner
- SWEENEY, MOLLY B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CONFOGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
B-9052 Zwijnaarde, BE
BE
BE
BE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jessica S. Sachs
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.5445 Corporate DriveSuite 200Troy, MI 48098Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substances, namely, antibodies for stabilization of proteins, all the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); proteins for use in science; chimeric proteins to measure, test and develop compounds and ligands binding to G protein-coupled receptors (GPCRs). | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteins, namely, small molecules and antibodies for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; veterinary products, namely, antigens and reagents for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases | ACTIVE | — |
| 035 | Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management. | ACTIVE | — |
| 042 | Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with g protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Confo Therapeutics NV
- Other trademarks owned by Confo Therapeutics N.V.
- Other trademarks owned by Confo Therapeutics N.V.
- Other trademarks owned by Confo Therapeutics N.V.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named CONFOGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 28, 2026 | IROP | IRREGULARITY ON NOTICE OF POSSIBLE OPPOSITION RECEIVED FROM IB | — |
| Jul 13, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 12, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 5, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 15, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 15, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 5, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 12, 2025 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Aug 5, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 5, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 17, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 17, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 14, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 12, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 12, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 12, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 5, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 16, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 15, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 14, 2025 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Feb 7, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 6, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2025 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Jan 31, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 1, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 31, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 27, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 27, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 26, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |